The launch of several novel therapies and multiple label expansions for premium-priced agents will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) / chronic lymphocytic leukemia (CLL…
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
NHL and CLL encompass a heterogeneous group of hematological malignancies broadly classified into indolent and aggressive subtypes. Treatment approaches vary by subtype, with rituximab in…
The launch of several novel therapies, as well as multiple label expansions of existing drugs, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) / chronic lymphocytic leukemia (…
Relapsed / refractory diffuse large B-cell lymphoma (R/R DLBCL) is an aggressive disease with significant unmet need. The treatment landscape has evolved since the approval of various novel…
Clarivate Epidemiology’s coverage of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) comprises epidemiological estimates of key patient populations in 45 countries worldwide…
DRG Epidemiology’s coverage of NHL comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of NHL for each country…
DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key NHL patient populations covering 171 countries and more than 99% of the…
Clarivate Epidemiology’s coverage of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) comprises epidemiological estimates of key patient populations in 45 countries worldwide…
Clarivate Epidemiology’s coverage of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) comprises epidemiological estimates of key patient populations in 45 countries worldwide…